Bardy Diagnostics (BardyDx) has today announced the commercial launch of the 14-Day version of the Carnation Ambulatory Monitor (CAM), the P-wave centric ambulatory cardiac patch monitor and arrhythmia detection device, following recent clearance by the FDA.
“The 14-Day CAM is the culmination of years of development focused on uncovering the full complexity and meaning of a patient’s cardiac rhythm,” said Gust H Bardy, MD, founder and chief executive officer of BardyDx. “We are proud to develop and introduce the most advanced and accurate cardiac monitoring technologies that enable new opportunities to reimagine and redefine patient care.”
In a press release the company said that strong market uptake of its P-wave centric solutions has spurred recent expansion of the company’s infrastructure to maintain its rapid pace. A second ECG monitoring centre located in New Jersey was established last quarter, which received Medicare enrolment approval by the Centers for Medicare & Medicaid Services effective December 2, 2019.
“We are extremely proud of the continued momentum of the CAM Patch becoming the cardiac monitor of choice and trusted solution of cardiologists and electrophysiologists across the US, UK, and Canada,” said Ken Nelson, chief commercial officer. “It is increasingly clear that customers are realising the true clinical and market-differentiating value of our P-wave focused detection technology in enabling optimal patient care.”